Holocene Advisors LP Sells 793,240 Shares of Elanco Animal Health Incorporated $ELAN

Holocene Advisors LP cut its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 27.5% during the third quarter, HoldingsChannel reports. The firm owned 2,093,054 shares of the company’s stock after selling 793,240 shares during the period. Holocene Advisors LP’s holdings in Elanco Animal Health were worth $42,154,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. SJS Investment Consulting Inc. increased its position in Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after buying an additional 1,333 shares during the period. Huntington National Bank boosted its position in shares of Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after acquiring an additional 1,087 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its position in shares of Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after acquiring an additional 900 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Elanco Animal Health by 79.3% in the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after acquiring an additional 951 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in shares of Elanco Animal Health by 3,018.3% in the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after acquiring an additional 2,807 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

ELAN opened at $23.40 on Tuesday. The stock’s 50 day simple moving average is $24.53 and its 200-day simple moving average is $22.28. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The stock has a market cap of $11.64 billion, a PE ratio of -48.76, a P/E/G ratio of 2.92 and a beta of 1.83. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $27.72.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period last year, the business earned $0.14 earnings per share. Elanco Animal Health’s quarterly revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ELAN. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Wednesday, November 19th. Piper Sandler upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. Morgan Stanley boosted their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. KeyCorp upped their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Finally, UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.67.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.